0001562180-23-001330.txt : 20230213 0001562180-23-001330.hdr.sgml : 20230213 20230213165653 ACCESSION NUMBER: 0001562180-23-001330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230209 FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lurker Nancy CENTRAL INDEX KEY: 0001450485 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 23619502 MAIL ADDRESS: STREET 1: PDI, INC. STREET 2: 1 ROUTE 17 SOUTH CITY: SADDLE RIVER STATE: NJ ZIP: 07458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2023-02-09 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001450485 Lurker Nancy C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 true true false false CEO Common Stock 2023-02-09 4 M false 17533.00 0.00 A 170559.00 D Common Stock 2023-02-09 4 M false 20000.00 0.00 A 190559.00 D Restricted Stock Units 0.00 2023-02-09 4 M false 20000.00 0.00 D Common Stock 20000.00 40000.00 D Restricted Stock Units 0.00 2023-02-09 4 M false 17533.00 0.00 D Common Stock 17533.00 17534.00 D Includes 2,745 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. The restricted stock units vest in three annual installments beginning February 9, 2023. The restricted stock units vest in three ratable annual installments beginning February 9, 2022. /s/ Ron Honig, Attorney-in-Fact 2023-02-13